Jamp Pharma Corporation Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Jamp Pharma Corporation Pharmaceutical Import Records from India — 14 Products, $13.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Jamp Pharma Corporation — Pharmaceutical Importer Profile (2026) | 14 Products, $13.3M Trade | TransData Nexus

Jamp Pharma Corporation

Pharmaceutical Importer · Canada · Cardiovascular Focus · $13.3M Total Trade · DGFT Verified

Jamp Pharma Corporation is a pharmaceutical importer based in Canada with a total trade value of $13.3M across 14 products in 9 therapeutic categories. Based on 401 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Jamp Pharma Corporation sources from 36 verified Indian suppliers, with Medreich Limited accounting for 26.5% of imports.

Jamp Pharma Corporation — Import Portfolio & Supplier Network

Jamp Pharma Corporation import network — 14 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Jamp Pharma Corporation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$13.5M	1,006	26.5%
Alembic Pharmaceuticals Limited	$6.4M	289	12.5%
Unison Pharmaceuticals Private Limited

What Formulations Does Jamp Pharma Corporation Import?

Formulation	Value	Ships
Emolax polythylene glycol 3350 powder for oral	$900.0K	18
Emolax polythylene glycol 3350 powder	$800.0K	16
Rosuvastatin 10MG film coated	$277.4K	9
Duloxetine CAPS. 60	$271.6K	12
Amoxicillin capsules BP 500MG (jamp	$265.1K	7
Rosuvastatin 20MG film coated	$259.3K	11
Emolax polythylene glycol 3350 powder for oral solution composition:polythyleneglycol 3350	$250.0K	5
Amoxicillin 875MG and clavulanic acid	$242.8K	8
Jamp-duloxetine dr	$242.2K	6
Gabapentin tablet USP 600 MG	$236.3K	9
Jamp-duloxetine dr	$231.0K	5
Cyclobenzaprine hydrochloride tablets	$226.3K	6
Atorvastatin 20MG film coated tablets	$221.0K	11
Atorvastatin 80MG film coated tablets (jamp atorvastatin 80MG tablets) 100s (8582 packs )	$208.3K	5
Pharma drugs and medi jamp-omeprazole	$206.1K	7

Jamp Pharma Corporation imports 1,846 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 14 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Dapagliflozin	Advanced Diabetes Medications	$3.0M	72	4.6%	4
2	Apixaban	Cardiovascular	$2.3M	71	1.3%	12
3	Acyclovir	Antivirals	$1.3M	37	1.0%	13
4	Valacyclovir	Antivirals	$1.3M	37	1.4%	8
5	Bisoprolol	Cardiovascular	$1.1M	28	1.3%	9
6	Natural	Ayurvedic & Herbal Products	$1.1M	25	3.1%	8
7	Salicylic	Combination Drugs	$841.7K	25	3.5%	7
8	Simvastatin	Cardiovascular	$569.3K	51	0.5%	17
9	Acetylsalicylic	Combination Drugs	$542.8K	14	8.3%	3
10	Temozolomide	Advanced Oncology	$321.0K	12	1.4%	14
11	Febuxostat	Lipid & Metabolism	$300.0K	6	0.6%	18
12	Nitrofurantoin	Advanced Antibiotics	$220.4K	9	0.6%	19
13	Pyrantel	Antimalarial & Antiparasitic	$180.5K	6	5.5%	5
14	Digoxin	Cardiovascular	$95.5K	8	3.3%	4

Jamp Pharma Corporation imports 14 pharmaceutical products across 9 categories into Canada totaling $13.3M.

Jamp Pharma Corporation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

JAMP Pharma Corporation, established in 1988, is a privately held Canadian pharmaceutical company headquartered in Boucherville, Quebec. Initially founded as a contract manufacturing organization (CMO), JAMP Pharma has evolved into a comprehensive provider of high-quality medicines and healthcare solutions for patients and consumers across Canada. (jamppharma.ca)

Under the leadership of CEO Louis Pilon, who acquired the company in 2006, JAMP Pharma has experienced significant growth, expanding its portfolio to include over 350 molecules and becoming a leader in the Canadian generic pharmaceutical industry. The company operates through various divisions, such as Orimed Pharma, BioJAMP, Wampole, Laboratoire Suisse, and Cosmetic Import, offering a diverse range of products, including generic medications, biosimilars, over-the-counter products, and natural health products. (jamppharma.ca)

2Distribution Network

JAMP Pharma's distribution network is robust, ensuring nationwide coverage across Canada. The company maintains a fully integrated commercial operation, including warehousing, quality assurance laboratories, and cold chain maintenance capabilities. This infrastructure supports the supply of over 11,500 pharmacies from coast to coast, demonstrating the company's commitment to providing reliable access to its products. (jamppharma.ca)

3Industry Role

In Canada's pharmaceutical supply chain, JAMP Pharma Corporation functions primarily as a wholesaler and distributor. The company imports a diverse range of pharmaceutical formulations, including tablets, capsules, syrups, and injections, from various international suppliers, notably from India. JAMP Pharma's extensive portfolio and distribution capabilities position it as a significant player in the Canadian pharmaceutical market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Jamp Pharma Corporation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

JAMP Pharma's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 68.8% of its total import value from India. This concentration indicates a strategic focus on specific high-demand therapeutic areas, such as cardiovascular, advanced diabetes medications, and antivirals. The company's reliance on a select group of suppliers, including MEDREICH LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, and UNISON PHARMACEUTICALS PRIVATE LIMITED, suggests a stable and established relationship with these partners. However, this dependency also presents potential risks, such as supply chain disruptions or price fluctuations.

2Supply Chain Resilience

JAMP Pharma's supply chain resilience is supported by its diversified portfolio of 1,846 unique formulations and a network of 36 verified Indian suppliers. This diversity mitigates risks associated with over-reliance on a single supplier or product. The company's established relationships with key suppliers, such as MEDREICH LIMITED and ALEMBIC PHARMACEUTICALS LIMITED, enhance supply chain stability. Additionally, JAMP Pharma's integrated operations, including warehousing and quality assurance laboratories, contribute to its ability to maintain a reliable supply of pharmaceutical products.

Strategic Implications

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the importation and sale of pharmaceutical products are regulated by Health Canada under the Food and Drugs Act and its associated Regulations. This framework ensures that all health products, including human drugs, medical devices, and natural health products, meet rigorous standards for safety, effectiveness, and quality. (canada.ca)

2Import Licensing & GMP

Importers of pharmaceutical products in Canada must obtain an Establishment Licence (EL) for the activity of importation. Additionally, each drug product must have a Drug Identification Number (DIN) assigned by Health Canada prior to being marketed. Good Manufacturing Practice (GMP) compliance is mandatory, and foreign manufacturing sites must be listed on the importer's EL. Recognized GMP certifications include EU GMP, WHO GMP, and PIC/S. (canada.ca)

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing to ensure they meet Health Canada's quality standards. Stability requirements are specified to ensure product efficacy and safety throughout its shelf life. Labeling must be in both English and French, as per Canadian regulations, and must include all necessary information, such as dosage instructions, ingredients, and expiry dates. Serialization mandates may apply to facilitate traceability and prevent counterfeit products.

Jamp Pharma Corporation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

JAMP Pharma's product strategy focuses on therapeutic areas with high market demand, including cardiovascular, advanced diabetes medications, and antivirals. The company's importation of specific products like Dapagliflozin, Apixaban, Acyclovir, Valacyclovir, and Bisoprolol aligns with this focus, addressing prevalent health conditions in Canada. This strategic approach ensures that JAMP Pharma meets the evolving needs of the Canadian healthcare system.

2Sourcing Profile

JAMP Pharma's sourcing strategy emphasizes the importation of generic drug formulations from India, leveraging the country's established pharmaceutical manufacturing capabilities. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) allows for a more streamlined supply chain and ensures product quality. India's compliance with recognized GMP standards, such as WHO GMP and PIC/S, aligns with JAMP Pharma's quality requirements.

3Market Positioning

JAMP Pharma Corporation serves multiple segments of the Canadian pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's extensive product portfolio and reliable supply chain enable it to meet the diverse needs of these segments, positioning JAMP Pharma as a versatile and dependable partner in the Canadian healthcare landscape.

Seller's Guide — How to Become a Supplier to Jamp Pharma Corporation

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter JAMP Pharma's supply chain, particularly in the cardiovascular, diabetes, and antiviral therapeutic areas. To capitalize on this opportunity, Indian exporters should focus on meeting Health Canada's regulatory requirements, including obtaining the necessary GMP certifications and ensuring compliance with labeling and quality standards. Establishing strong relationships with JAMP Pharma and understanding its specific product needs will be crucial for successful market entry.

2Requirements & Qualifications

Indian exporters aiming to supply JAMP Pharma Corporation must obtain GMP certifications recognized by Health Canada, such as EU GMP, WHO GMP, or PIC/S. They must also ensure that their products meet Health Canada's quality standards, including batch testing and stability requirements. Labeling must be in both English and French, as per Canadian regulations. Additionally, exporters must be prepared to obtain a Drug Identification Number (DIN) for each product prior to marketing in Canada. (canada.ca)

3How to Approach

Frequently Asked Questions — Jamp Pharma Corporation

What products does Jamp Pharma Corporation import from India?

Jamp Pharma Corporation imports 14 pharmaceutical products across 9 categories. Top imports: Dapagliflozin ($3.0M), Apixaban ($2.3M), Acyclovir ($1.3M), Valacyclovir ($1.3M), Bisoprolol ($1.1M).

Who supplies pharmaceuticals to Jamp Pharma Corporation from India?

Jamp Pharma Corporation sources from 36 verified Indian suppliers. The primary supplier is Medreich Limited (26.5% of imports, $13.5M).

What is Jamp Pharma Corporation's total pharmaceutical import value?

Jamp Pharma Corporation's total pharmaceutical import value from India is $13.3M, based on 401 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Jamp Pharma Corporation focus on?

Jamp Pharma Corporation imports across 9 categories. The largest: Cardiovascular (31.1%), Advanced Diabetes Medications (22.9%), Antivirals (19.8%).

Get Full Jamp Pharma Corporation Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.